Would you consider stopping EGFR inhibitor in EGFR mutant NSCLC on a patient who was NED for >5 years?

Community
Company
News
Contact Us
Sign in

Topics: Thoracic Malignancies • Medical Oncology

68F who has been on afatinib for 6 years. Has been NED on CT, PET and MRI for > 5 years. Had isolated T-spine mets (radiated) and primary right hilar mass that have all resolved.

Related Questions

What second line therapy do you use for metastatic thymoma that recurs following CAP?

How would you treat a patient with progressive ALK (+) NSCLC that has MET Exon 14 deletion upon repeat molecular testing on metastatic site?

What systemic therapy would you offer to a patient with metastatic EGFR exon 19 deleted NSCLC to the brain with isolated CNS progression while on osimertinib 80 mg and progressed through WBRT?

Would you offer adjuvant osimertinib in a patient with complete pathologic response to neoadjuvant platinum doublet for a stage IIIA resected EGFR mutant lung adenocarcinoma?

How often, if ever, do patients with initially negative targetable mutation workup become positive later in recurrent lung cancer?

What is the role for molecular agents alone for medically inoperable NSCLC who is not a good candidate for chemoRT?

Would you consider adjuvant osimertinib for patients with non-classical but sensitizing EGFR mutation positive NSCLC s/p surgical resection?

In light of the FLAURA2 data, which patients would you recommend upfront treatment with chemotherapy + osimertinib rather than osimertinib monotherapy?

How would you manage a patient with radiation pneumonitis who remains symptomatic on steroids?

Would you consider omission of PORT for node+ NSCLC with a positive margin in the setting of a high tumor PD-L1 score and plans for immunotherapy?